Limitations of the current study include the lack of data regarding the relationship of ADAM6 and/or PRSS1 levels with overall survival (OS) and relapse-free survival (RFS), as well as not providing in-depth profiling for ADMA6 and/or PRSS1 in different genetic subtypes of AML or ALL. Here, ADAM6 is linked to acute myeloid leukemia.